Q2 2022 EPS Estimates for Axsome Therapeutics, Inc. (NASDAQ:AXSM) Decreased by Analyst

Axsome Therapeutics, Inc. (NASDAQ:AXSMGet Rating) – Analysts at SVB Leerink cut their Q2 2022 earnings per share estimates for Axsome Therapeutics in a research note issued on Thursday, April 21st. SVB Leerink analyst M. Goodman now forecasts that the company will post earnings of ($1.09) per share for the quarter, down from their prior estimate of ($1.05). SVB Leerink has a “Outperform” rating and a $50.00 price objective on the stock. SVB Leerink also issued estimates for Axsome Therapeutics’ Q3 2022 earnings at ($1.07) EPS, Q4 2022 earnings at ($1.25) EPS, FY2022 earnings at ($4.25) EPS and FY2023 earnings at ($5.50) EPS.

A number of other equities analysts also recently weighed in on AXSM. StockNews.com initiated coverage on shares of Axsome Therapeutics in a research note on Thursday, March 31st. They set a “sell” rating for the company. Zacks Investment Research downgraded shares of Axsome Therapeutics from a “buy” rating to a “hold” rating and set a $32.00 target price for the company. in a research note on Friday, March 4th. Finally, Jefferies Financial Group lifted their target price on shares of Axsome Therapeutics from $71.00 to $77.00 and gave the stock a “buy” rating in a research note on Tuesday, March 29th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $80.78.

Shares of NASDAQ AXSM opened at $39.10 on Monday. Axsome Therapeutics has a twelve month low of $19.38 and a twelve month high of $74.10. The firm has a fifty day simple moving average of $34.91 and a 200 day simple moving average of $34.57. The company has a market capitalization of $1.50 billion, a PE ratio of -11.27 and a beta of 2.41. The company has a quick ratio of 3.75, a current ratio of 3.75 and a debt-to-equity ratio of 3.14.

Axsome Therapeutics (NASDAQ:AXSMGet Rating) last announced its earnings results on Tuesday, March 1st. The company reported ($0.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.09. During the same quarter in the prior year, the company posted ($0.78) EPS.

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. increased its position in shares of Axsome Therapeutics by 2.0% during the fourth quarter. BlackRock Inc. now owns 2,109,622 shares of the company’s stock worth $79,700,000 after acquiring an additional 41,559 shares in the last quarter. Bellevue Group AG increased its position in shares of Axsome Therapeutics by 113.9% during the third quarter. Bellevue Group AG now owns 752,945 shares of the company’s stock worth $24,817,000 after acquiring an additional 400,924 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Axsome Therapeutics by 3.3% during the fourth quarter. Geode Capital Management LLC now owns 507,485 shares of the company’s stock worth $19,172,000 after acquiring an additional 16,055 shares in the last quarter. Nuveen Asset Management LLC increased its position in shares of Axsome Therapeutics by 55.3% during the fourth quarter. Nuveen Asset Management LLC now owns 494,206 shares of the company’s stock worth $18,671,000 after acquiring an additional 175,949 shares in the last quarter. Finally, Morgan Stanley increased its position in shares of Axsome Therapeutics by 15.3% during the third quarter. Morgan Stanley now owns 365,969 shares of the company’s stock worth $12,062,000 after acquiring an additional 48,523 shares in the last quarter. 48.45% of the stock is owned by hedge funds and other institutional investors.

Axsome Therapeutics Company Profile (Get Rating)

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation.

See Also

Earnings History and Estimates for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.